Single-dose zanzalintinib testing in people with moderate liver impairment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional study gives a single dose of zanzalintinib and measures plasma pharmacokinetics in participants with moderate hepatic impairment versus matched healthy volunteers. Participants with moderate impairment are defined by Child-Pugh Class B (score 7–9) and must otherwise have no clinically significant medical history and meet bone marrow and smoking restrictions. Serial blood samples are collected after dosing to characterize absorption, distribution, metabolism, and elimination parameters, while safety is monitored. The trial is conducted at two Exelixis clinical sites in Orlando, FL and San Antonio, TX.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* All Participants:

  * No clinically significant medical history (aside from the HI for participants in the HI group only), physical examination findings, or vital signs, as deemed by the investigator.
  * A continuous non-smoker or moderate smoker who smokes ≤ 10 cigarettes, ≤ 2 cigars, or ≤2 pipes per day and agree to limit smoking during the confinement period to ≤ 4 cigarettes or ≤1 cigar or pipe per day. Participant must agree to maintain the same smoking status (smoker or non-smoker) from screening and until after the last PK sample collection.
  * Has not donated blood within 30 days of dosing or plasma within 7 days of dosing and must agree to refrain from blood donation until at least 30 days following dosing.
* Participants with Moderate HI Only:

  * Adequate bone marrow function, at the screening and dosing visit.
  * Is classified as having moderate HI by the Child-Pugh classification system (Class B, score of 7 to 9, inclusive) and has a total bilirubin value within the range of \> 1.5\* upper limit of normal (ULN) and ≤ 3\* ULN at the screening and dosing visit.
  * Has a diagnosis of chronic (\> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency at the screening visit with features of cirrhosis due to any etiology.
* Healthy Control Participants Only:

  * Age must be within ± 10 years of the mean age of participants with moderate HI. The sex ratio (male/female ratio), and smoking status ratio (smokers/non-smokers ratio) must be the same to the sex and smoking status ratio of participants with moderate HI.

Key Exclusion Criteria:

* All Participants:

  * • History of any medical or surgical conditions that would potentially alter absorption, distribution, metabolism, and/or excretion of orally administered drugs.
  * Has or is at risk for major cardiac events or dysfunction.
* Participants with Moderate HI Only:

  * History of liver or other solid organ transplant.
  * Fluctuating or rapidly deteriorating hepatic function (the definition of the change of more than 1 Child-Pugh point) within 30 days prior to Day 1, in the opinion of the investigator and Sponsor.
  * Symptoms or history of Grade 3 or worse degree of encephalopathy within 3 months of dosing.
  * Clinical evidence of severe ascites at the screening visit or at check in.
* Healthy Control Participants Only:

  * History or presence of alcohol or drug abuse within the past 2 years prior to dosing.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Where it's running

• Exelixis Clinical Site #1
  Orlando, Florida, United States Recruiting
• Exelixis Clinical Site #2
  San Antonio, Texas, United States Recruiting

Study contacts

• Study coordinator: Exelixis Clinical Trials
• Email: druginfo@exelixis.com
• Phone: 1-888-EXELIXIS (888-393-5494)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Casdatifan pharmacokinetics in moderate hepatic impairment vs normal liver function

  This study tests how a single dose of casdatifan behaves in people with moderate liver impairment compared to healthy individuals with normal liver function.

  Recruiting Phase 1 Arcus Biosciences, Inc. · San Antonio, Texas · NCT07751250

• Zanzalintinib alone or with Pembrolizumab and Berahyaluronidase Alfa in colorectal cancer with molecular residual disease

  This trial tests whether zanzalintinib alone or with pembrolizumab and berahyaluronidase alfa can help people with stage II/III colorectal cancer who still have MRD detected by a Signatera test after surgery.

  Recruiting at 13 sites Phase 3 Exelixis · Council Bluffs, Iowa and 12 other locations · NCT07750158

• How the medicine Atirmociclib behaves in people with healthy liver or with liver disease

  This study tests how atirmociclib is processed in the body and how safe it is for adults with normal liver function or with stable mild to severe liver disease.

  Recruiting at 3 sites Phase 1 Pfizer · Miami Lakes, Florida and 2 other locations · NCT07677358

• Treprostinil Palmitil Inhalation Powder: how liver function affects drug in a single-dose test

  This study tests how mild to severe liver impairment changes the amount of treprostinil palmitil and treprostinil in the body after one 80 mcg dose of TPIP in people with and without liver problems.

  Recruiting at 4 sites Phase 1 Insmed Incorporated · Lake Forest, California and 3 other locations · NCT07643155

• How liver impairment affects AZD9550 and AZD6234

  This trial will test how single subcutaneous doses of two investigational drugs, AZD9550 and AZD6234, are processed and tolerated in adults with moderate or severe liver impairment compared with matched healthy volunteers.

  Recruiting at 3 sites Phase 1 AstraZeneca · Chandler, Arizona and 3 other locations · NCT07546760

• Zanzalintinib for Recurrent or Metastatic Olfactory Neuroblastoma

  This study tests whether zanzalintinib can help control recurrent or metastatic olfactory neuroblastoma and whether it is safe.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07527169

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.